What is the primary driver behind the reported revenue decline in Q2 2007?

The primary driver of the revenue decline in Q2 2007 was the loss of market exclusivity for key products such as Zoloft and Norvasc, coupled with increased competitive pressures on Lipitor. These factors significantly impacted sales of established blockbuster drugs.

How is the 'Adapting to Scale' (AtS) initiative impacting Pfizer's financial performance?

The AtS initiative is a significant cost-saving and efficiency program. While it is designed to improve long-term profitability, it resulted in substantial restructuring and implementation costs in Q2 2007, contributing to the decline in net income. These costs are expensed as the initiative progresses and aims to create a leaner, more productive operational structure.

What is the outlook for new product growth, and how is it offsetting the revenue loss from older products?

Pfizer is experiencing strong growth from newer products like Chantix/Champix and Lyrica, which are helping to offset declines from products losing exclusivity. The company continues to invest in R&D and pursue strategic acquisitions and collaborations to build a robust pipeline and drive future revenue growth.

What is the company's strategy regarding share repurchases and dividends?

Pfizer continues to return capital to shareholders through share repurchases and dividends. In Q2 2007, the company repurchased approximately 96.8 million shares for about $2.6 billion under its authorized program, indicating a commitment to enhancing shareholder value.

PFE 10-Q Quarterly Report Q3 FY2007 — Revenue, Net Income, EPS

Summary

Pfizer Inc. reported revenues of $11.08 billion for the second quarter of 2007, a decrease of 6% compared to the same period in 2006. For the first six months of 2007, revenues were comparable to the prior year at $23.56 billion. The decline in revenue was primarily driven by the loss of exclusivity for key products like Zoloft and Norvasc, and increased competition for Lipitor, partially offset by the strong performance of newer products such as Chantix/Champix and Lyrica, and favorable foreign exchange rates. Net income for the quarter was $1.27 billion, a significant decrease from $2.41 billion in the prior year, largely due to increased restructuring charges associated with the Adapting to Scale (AtS) productivity initiative, higher R&D expenses, and the absence of one-time tax benefits seen in the prior year. The company continues to execute its strategic initiatives, including acquisitions and cost-saving programs, aimed at improving efficiency and driving future growth.

Key Highlights

1Q2 2007 revenues decreased by 6% to $11.08 billion, with the first six months showing comparable revenues to the prior year ($23.56 billion).
2Net income for Q2 2007 significantly declined by 48% to $1.27 billion, compared to $2.41 billion in Q2 2006.
3Key products like Zoloft and Norvasc experienced significant revenue declines due to loss of exclusivity, while newer products like Chantix/Champix and Lyrica showed strong growth.
4Restructuring charges and Adapting to Scale (AtS) productivity initiative costs increased substantially in Q2 2007 ($1.35 billion) compared to Q2 2006 ($442 million).
5Research and Development (R&D) expenses increased by 24% in Q2 2007, driven by upfront payments for collaborations and AtS implementation costs.
6The company continued its share repurchase program, buying back approximately 96.8 million shares for about $2.6 billion in Q2 2007.
7Pfizer completed the acquisition of Embrex, Inc. and BioRexis Pharmaceutical Corp. in Q1 2007, contributing to growth in the Animal Health segment and pipeline development.

PFIZER INC Quarterly Report for Q3 Ended Jul 1, 2007

Summary

Key Highlights

Frequently Asked Questions